{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:17:16Z","timestamp":1793575036747,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40257-023-00801-8","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T10:01:40Z","timestamp":1687341700000},"page":"865-873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-2636","authenticated-orcid":false,"given":"Anna","family":"Aronovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5524-3603","authenticated-orcid":false,"given":"Ilya","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-9587","authenticated-orcid":false,"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"issue":"2","key":"801_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"801_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370. https:\/\/doi.org\/10.1056\/NEJMra1505557.","journal-title":"N Engl J Med"},{"issue":"4","key":"801_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","volume":"8","author":"A Zabotti","year":"2021","unstructured":"Zabotti A, De Lucia O, Sakellariou G, et al. Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis. Rheumatol Ther. 2021;8(4):1519\u201334. https:\/\/doi.org\/10.1007\/s40744-021-00378-w.","journal-title":"Rheumatol Ther."},{"key":"801_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/art.39494","volume":"68","author":"L Eder","year":"2016","unstructured":"Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68:915\u201323. https:\/\/doi.org\/10.1002\/art.39494.","journal-title":"Arthritis Rheum"},{"key":"801_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","volume":"61","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233\u20139. https:\/\/doi.org\/10.1002\/art.24172.","journal-title":"Arthritis Rheum"},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","volume":"52","author":"A Ogdie","year":"2013","unstructured":"Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford). 2013;52:568\u201375. https:\/\/doi.org\/10.1093\/rheumatology\/kes324.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"801_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341. https:\/\/doi.org\/10.1007\/s40265-014-0191-y.","journal-title":"Drugs"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/s0190-9622(03)01145-9","volume":"49","author":"EM Ruderman","year":"2003","unstructured":"Ruderman EM. Evaluation and management of psoriatic arthritis: the role of biologic therapy. J Am Acad Dermatol. 2003;49:S125\u201332. https:\/\/doi.org\/10.1016\/s0190-9622(03)01145-9.","journal-title":"J Am Acad Dermatol"},{"key":"801_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","volume":"73","author":"R Goulabchand","year":"2014","unstructured":"Goulabchand R, Mouterde G, Barnetche T, et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2014;73:414\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202641.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"801_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","volume":"41","author":"PJ Mease","year":"2015","unstructured":"Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):723\u201338. https:\/\/doi.org\/10.1016\/j.rdc.2015.07.010.","journal-title":"Rheum Dis Clin N Am"},{"issue":"8","key":"801_CR11","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. CASPAR study group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"801_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archdermatol.2007.28","volume":"144","author":"JK Robinson","year":"2008","unstructured":"Robinson JK, Dellavalle RP, Bigby M, et al. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol. 2008;144(1):97\u20139. https:\/\/doi.org\/10.1001\/archdermatol.2007.28.","journal-title":"Arch Dermatol"},{"issue":"1","key":"801_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","volume":"81","author":"ML Acosta Felquer","year":"2022","unstructured":"Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220865.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"801_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219961.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"801_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/art.41946","volume":"74","author":"YS Rosenthal","year":"2022","unstructured":"Rosenthal YS, Schwartz N, Sagy I, et al. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study. Arthritis Rheum. 2022;74(2):237\u201343. https:\/\/doi.org\/10.1002\/art.41946.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"801_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","volume":"81","author":"E Meer","year":"2022","unstructured":"Meer E, Merola JF, Fitzsimmons R, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220761.","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"801_CR17","doi-asserted-by":"publisher","first-page":"adv00324","DOI":"10.2340\/00015555-3682","volume":"100","author":"I Lindberg","year":"2020","unstructured":"Lindberg I, Lilja M, Geale K, et al. Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in Swedish routine clinical care. Acta Derm Venereol. 2020;100(18):adv00324. https:\/\/doi.org\/10.2340\/00015555-3682.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"801_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","volume":"86","author":"JF Merola","year":"2022","unstructured":"Merola JF, Tian H, Patil D, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health. J Am Acad Dermatol. 2022;86(4):748\u201357. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.019.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"801_CR19","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.jaad.2022.09.044","volume":"88","author":"M Chen","year":"2023","unstructured":"Chen M, Dai SM. Biologic treatment for psoriasis is unlikely to facilitate psoriatic arthritis development. J Am Acad Dermatol. 2023;88(1):e57\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.044.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"801_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-017-0706-0","volume":"20","author":"T Soleymani","year":"2017","unstructured":"Soleymani T, Reddy SM, Cohen JM, et al. Early recognition and treatment heralds optimal outcomes: the benefits of combined rheumatology-dermatology clinics and integrative care of psoriasis and psoriatic arthritis patients. Curr Rheumatol Rep. 2017;20(1):1. https:\/\/doi.org\/10.1007\/s11926-017-0706-0.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"801_CR21","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s10067-020-05482-w","volume":"40","author":"E Lubrano","year":"2021","unstructured":"Lubrano E, Delle Sedie A, Romanelli M, et al. Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clin Rheumatol. 2021;40(6):2251\u201362. https:\/\/doi.org\/10.1007\/s10067-020-05482-w.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"801_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.940330","volume":"9","author":"K Honeyford","year":"2022","unstructured":"Honeyford K, Expert P, Mendelsohn E, et al. Challenges and recommendations for high quality research using electronic health records. Front Digit Health. 2022;9(4): 940330. https:\/\/doi.org\/10.3389\/fdgth.2022.940330.","journal-title":"Front Digit Health."},{"issue":"3","key":"801_CR23","first-page":"Article 10","volume":"23","author":"JR Shah","year":"2014","unstructured":"Shah JR, Murtaza MB, Opara E. Electronic health records: challenges and opportunities. J Int Technol Inform Manage. 2014;23(3):Article 10.","journal-title":"J Int Technol Inform Manage."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00801-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T07:20:01Z","timestamp":1697095201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00801-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00801-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"28 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article or the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lev Pavlovsky has served as an investigator for Abbvie, Coherus, Novartis Pharmaceuticals Corporation, Janssen Biotech, Eli Lilly, and Bristol Myers Squibb and as an advisor, consultant, and\/or invited lecturer for Abbvie, Janssen Biotech, Novartis Pharmaceuticals Corporation, Pfizer Inc., Dexcel Pharma, Eli Lilly, Bristol Myers Squibb, Neopharm, and Boehringer Ingelheim. Anna Aronovich and Ilya Novikov have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AA: literature search and data analysis, drafting and critical revision of the work; IN: literature search and data analysis; LP: concept of the article, critical revision of the work. All authors approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}